NuVasive Inc

NuVasive — Investor Presentation (June 2020)

13 slides from NuVasive's investor presentation, Jun 4, 2020

  1. Slide 1: Investor Presentation

    NuVasive, Inc. Investor Presentation June 4, 2020 ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Forward-looking statements ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward‐looking statements that involve

  3. Slide 3: Non-GAAP financial measures

    Non-GAAP financial measures ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Management uses certain non-GAAP financial measures such as non-GAAP diluted earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating margin, which exclude amortizati

  4. Slide 4: Transform surgery. Advance care. Change lives.

    ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Transform surgery. Advance care. Change lives.

  5. Slide 5: Largest global, spine-focused company

    Largest global, spine-focused company 50+ international markets1 ~2,800 global employees1 A leader in minimally invasive surgery (MIS) and lateral surgery 15+ years of industry-leading technologies 2x growth of global spine market2 ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserve

  6. Slide 6: Continue to lead in MIS spine surgery; take share in targeted, open segments

    Continue to lead in MIS spine surgery; take share in targeted, open segments Cervical2 ~95% ~5% Complex2 ~93% ~7% TLIF/PLIF2 ~97% ~3% ALIF2 ~20% ~80% Open ~$8.5 billion1 0 - 2% growth ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. Invest and penetrate open surgery segments (c

  7. Slide 7: First quarter 2020 financial results

    First quarter 2020 financial results ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. $259.9M (5.4%) Reported revenue 16.9% Non-GAAP operating margin $0.48 Non-GAAP diluted earnings per share Q1 2020 Results Business Line Revenue Growth Rates1 U.S. Spinal Hardware: (6.3%) U.S.

  8. Slide 8: COVID-19 impact trends taking shape, but still many unknowns

    COVID-19 impact trends taking shape, but still many unknowns What we do and don’t know NuVasive withdrew its annual financial guidance for 2020 In the U.S. and globally, many hospitals have restarted elective procedures in a measured way The recovery of volumes lacks uniformity and highly variable b

  9. Slide 9: COVID-19 impact on the business

    COVID-19 impact on the business Company implemented safety measures across the organization Created COVID-19 response team to track impact and enacted cost-savings initiatives expected throughout remainder of 2020, including: Executive and Board pay reductions T&E and discretionary spend reductions

  10. Slide 10: COVID-19 impact on case volumes

    COVID-19 impact on case volumes First quarter 2020 net sales were tracking to expectations until mid-March Case volumes experienced a sharp decline starting in mid-March as COVID-19 led to deferrals of elective surgeries While procedure volumes in January and February were strong, net sales for Q1 2

  11. Slide 11: Growth priorities

    Growth priorities Advance leadership in less invasive surgery Expand portfolio with best-in-class technology Achieve scale in key global markets ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved.

  12. Slide 12: Balance sheet and liquidity to support global growth strategy

    Balance sheet and liquidity to support global growth strategy > $900.0M in cash and cash equivalents Net debt leverage ratio of 2.71 $550.0M of capacity under credit facility ©2020. NuVasive, Inc. or one of its subsidiaries. All rights reserved. NuVasive issued: $450 million of 0.375% convertible se

  13. Slide 13: Capital allocation strategy

    Capital allocation strategy R&D to fuel competitive advantage and price protection Innovation Procedural assets and company infrastructure Capital expenditures Authorized to repurchase additional $75M through 2021 Share repurchases Differentiated technology, advanced capabilities and geographic expa

Nuvasive — Investor Presentation (June 2020) on 6ix